Journal article
Therapeutic cancer vaccines based on molecularly defined human tumor antigens.
- Romero P Divison of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital, Avenue Pierre-Decker 4, 1005 Lausanne, Switzerland. pedro.romero@isrec.unil.ch
- Pittet M
- Dutoit V
- Zippelius A
- Liénard D
- Lejeune F
- Guillaume P
- Rimoldi D
- Valmori D
- Speiser DE
- Cerottini JC
- 2002-12-13
Published in:
- Vaccine. - 2002
Antigens, Neoplasm
Cancer Vaccines
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Humans
T-Lymphocytes, Cytotoxic
English
The results of numerous phases I and II clinical trials testing the safety and immunogenicity of various cancer vaccine formulations based on cytolytic T lymphocytes (CTLs)-defined tumor antigens have been reported recently. Specific T cell responses can be detected in only a fraction of immunized patients. A smaller but significant fraction of these patients have objective tumor responses. Efficient therapeutic vaccination should aim at boosting naturally occurring anti-tumor responses and at sustaining a large contingent of tumor antigen-specific and fully functional effector T cells at tumor sites.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1016/s0264-410x(02)00380-8
- PMID 12477422
- Persistent URL
- https://sonar.ch/global/documents/139171
Statistics
Document views: 22
File downloads: